Sage Therapeutics

💊 Neuropharmaceuticals· 📍 Cambridge, MA, USA

Overview

Sage Therapeutics is a biopharmaceutical company pioneering GABA and NMDA receptor-targeted medicines for brain health disorders, with Zurzuvae (zuranolone) being the first once-daily oral pill FDA-approved for postpartum depression. They continue to advance a pipeline targeting major depressive disorder, epilepsy, and essential tremor.

More in Neuropharmaceuticals

Cortexyme Inc.

San Francisco, CA, USA

Neuralstem Inc.

Germantown, MD, USA

Neurogenix Therapeutics

Basel, Switzerland

Acadia Pharmaceuticals

San Diego, USA

Acer Therapeutics

Newton, MA, USA

Praxis Precision Medicine

Cambridge, MA, USA

Latest industry news

Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Target Brain Health

2026-07-11 · Funding

BrainCo Pushes to Commercialize Brain-Tech as China's BCI Ambitions Come Into Focus

2026-07-10 · Industry

FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical Reach

2026-07-09 · Policy

Neurovalens Wins FDA Approval for PTSD Therapy Targeting US Veterans

2026-07-08 · Policy

Company details

Is this your company?

Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.

Claim & upgrade listing

Advertise

Reach neurotech professionals

Newsletter sponsorships, featured listings, and sponsored articles.

View packages →